Echocardiography could soon be out of the hospital block to enter city firms, rural care centers, or emergency services. It is the ambition of the Bordeaux startup Deskiwhich has just raised 5.2 million euros in seed to deploy Heartfocusits cardiac imaging software assisted by artificial intelligence, recently approved by the FDA.
Faced with the global shortage of cardiologists and technicians specializing in imaging, the company wants to allow any healthcare professional formed in a few hours to carry out exploitable cardiac ultrasounds. The software Operator’s hand in real time guideautomatically identifies diagnostic views, and produces reliable results without requiring expert skills. A rupture made possible by a base of more than 10 million data points and rigorous clinical validation.
“This funding brings us closer to a world where early screening for heart disease is possible at all levels of care,” said Bertrand moalCEO and co -founder of Deski. “It allows us to continue to improve Heartfocus and guarantees that more caregivers will have access to the tools necessary to make vital diagnoses. »»
With Heartfocus, the startup targets a massive public health issue namely Cardiovascular diseases remain the leading cause of mortality in the worldwhile access to echocardiography is often reserved for hospitals. Deski’s technology wants to fill this structural vacuum by offering a light software solution, integrated into existing clinical platforms and ready for large -scale adoption.
The recent FDA authorization is accompanied by a Predermined Change Control Plan (PCCP)which will allow the company to update its software continuously, without ironing with heavy approval cycles. This regulatory framework strengthens the commercial viability of a product which, according to its promoters, has already proven that it allowed novice users to produce clinically valid examinations from the first use.
Léa ZaslavskyPartner at Racine2, the impact fund that leads this tour de table, underlines: “With Heartfocus, Deski attacks one of the greatest current health challenges: making the vital diagnosis accessible far beyond the walls of the hospital. We are proud to support the transition from clinical validation to real impact. »»
On the investor side, BNP Paribas Development,, Epic management,, Good Only Ventures,, Beetle And Naco (New Aquitaine Regional Fund advised by M Capital) also participate in this turn.
